scholarly journals Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience

2017 ◽  
Author(s):  
Şeniz Öngören ◽  
Ahmet Emre Eşkazan ◽  
Selin Berk ◽  
Tuğrul Elverdi ◽  
Ayşe Salihoğlu ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Treatment Modalities ◽  
Line Treatment ◽  
Hairy Cell ◽  
Retrospective Evaluation ◽  
Cell Leukemia ◽  
Single Center ◽  
First Line ◽  
Single Center Experience ◽  
First Line Treatment

Efficacy of Rituximab in Hairy Cell Leukemia.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4719-4719
Author(s):  
Styliani I. Kokoris ◽  
Maria K. Angelopoulou ◽  
Zacharoula I. Galani ◽  
Konstantinos Anargyrou ◽  
Sotirios Sachanas ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Interferon Alpha ◽  
Hairy Cell Leukemia ◽  
Response Rate ◽  
Costal Margin ◽  
Line Treatment ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
First Line ◽  
First Line Treatment

Abstract BACKGROUND: Hairy Cell Leukemia (HCL) is a rare B-chronic lymphoproliferative disorder (BCLD) with an indolent course. First-line treatment modalities include 2-chlorodeoxyadenosine (2-CDA), 2-deoxycoformycin (2-DCF) and interferon-alpha. The efficacy of anti-CD20-Rituximab (R) in other BCLDs, as well as strong CD20 expression by HCL cells, indicate that R could be an alternative treatment of HCL. AIMS: The experience of a single Hematology Unit in the treatment of relapsed HCL with R. PATIENTS AND METHODS: We retrospectively analyzed all HCL patients (pts) who received R as salvage therapy in 1st or subsequent relapse. RESULTS: 13 patients treated with R were located among 110 patients diagnosed with HCL between 1980 and 2005. 11 were males and their median age before R treatment was 46 years (range: 42–88). 5 pts had splenomegaly with a median spleen size of 7cm below left costal margin (range:5–20cm). 3 pts has an absolute neutrophil count<1.5×109/L, 4 a hemoglobin <10g/dL and 5pts a platelet count<100×109/L. All patients displayed a typical immunophenotype from blood and/or bone marrow (CD20 strongly +, CD19+, CD22+, FMC-7+, CD11c+, CD25+, CD103+). Four of them were CD23+ and two CD10+. 8 pts received Rituximab at 1st relapse. Among them, one had received 2-DCF as first-line treatment, one 2-CDA and 6 interferon-alpha as induction and maintenance. 3 pts had received more than one prior treatments. Two pts received R at diagnosis, due to older age. The median time from diagnosis to R initiation was 61 months (range: 4–275). R was administered at 375mg/m2 weekly for 6 cycles. Overall response rate was 67%, with 4 pts showing a negative immunophenotype. One pt discontinued treatment after the first cycle due to the development of thrombocytopenia that was attributed to the drug. 7/8 responders showed a complete restoration of their cytopenias. No other complications were recorded, except of mild infusion-related symptoms. Among the responding pts, none has relapsed so far with a median follow-up of 14 months (range: 4–40+). Among partial responders, one achieved a complete response including a negative bone marrow and immunophenotype after R retreatment. CONCLUSIONS: R is a highly effective and tolerable treatment for HCL in relapse with a response rate of 67%. Retreatment or maintenance with R may be important, since ongoing responses are seen.

scholarly journals Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases

Oncotarget ◽  
2017 ◽  
Vol 8 (66) ◽  
pp. 110727-110731 ◽  
Author(s):  
Andrea Visentin ◽  
Silvia Imbergamo ◽  
Federica Frezzato ◽  
Marco Pizzi ◽  
Roberta Bertorelle ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Line Treatment ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
First Line ◽  
First Line Treatment

Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience

2013 ◽  
Vol 30 (1) ◽  
Author(s):  
Lorenzo Livi ◽  
Pierluigi Bonomo ◽  
Icro Meattini ◽  
Gabriele Simontacchi ◽  
Daniela Greto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Single Center ◽  
First Line ◽  
Single Center Experience ◽  
First Line Treatment

Efficacy of antithymocyte globulin as first-line treatment for aplastic anemia—a single-center experience

2017 ◽  
Vol 97 (4) ◽  
pp. 727-730
Author(s):  
I. A. van Zeventer ◽  
J. W. G. M. Schreurs ◽  
E. van den Berg ◽  
A. B. Mulder ◽  
E. Vellenga ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Line Treatment ◽  
Single Center ◽  
First Line ◽  
Single Center Experience ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document